The Breast Cancer Research Foundation (BCRF) will commit $60.2 million to breast cancer research in 2023-2024, supporting more than 250…
NOTICIAS
A new joint effort by the Hospital del Mar Research Institute, the Vall d’Hebron Institut d’Oncologia (VHIO), IDIBELL, and the…
Inaugurated by Andrés Cervantes (Valencia, Spain), President of the European Society for Medical Oncology (ESMO) and ESMO Congress 2023, this…
Reported today at the ESMO Congress 2023 in Madrid, results of a VHIO prospective study point to the promise of…
Presented during Presidential session I (1) at the 2023 Congress of the European Society for Medical Oncology (ESMO), 20-24 October…
Presented today at the ESMO Congress 2023, results of the phase III LITESPARK-005 study show that treatment with belzutifan versus…
Josep Tabernero, Director of the Vall d’Hebron Institute of Oncology (VHIO) has been appointed chairman of the European consortium Cancer…
Developed by VHIO investigators, VIGex is a gene expression signature that classifies solid tumors into three categories based on the…
Chemotherapy resistance is often driven by cancer cells entering into a slow-cycling or dormant state to evade therapy-induced cell death….
Network Aims to Advance Collaboration Across Industry and Academia to Accelerate Treatment Development for Patients Inaugural Scientific Summit Prioritized Advancing…
